5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Open Access
- 16 September 2010
- Vol. 2 (3), 1717-1730
- https://doi.org/10.3390/cancers2031717
Abstract
5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a continuous intravenous infusion. Recent clinical chemotherapy studies have shown that several of the regimens with oral 5-FU drugs are not inferior compared to those involving continuous 5-FU infusion chemotherapy, and it is probable that in some regimens continuous 5-FU infusion can be replaced by oral 5-FU drugs. Historically, both the pharmaceutical industry and academia in Japan have been involved in the development of oral 5-FU drugs, and this review will focus on the current knowledge of 5-FU anabolism and catabolism, and the available information about the various orally-administrable 5-FU drugs, including UFT, S-1 and capecitabine. Clinical studies comparing the efficacy and adverse events of S-1 and capecitabine have been reported, and the accumulated results should be utilized to optimize the treatment of cancer patients. On the other hand, it is essential to elucidate the pharmacokinetic mechanism of each of the newly-developed drugs, to correctly select the drugs for each patient in the clinical setting, and to further develop optimized drug derivatives.Keywords
This publication has 54 references indexed in Scilit:
- Oral Fluoropyrimidines (Capecitabine or S-1) and Cisplatin as First Line Treatment in Elderly Patients with Advanced Gastric Cancer: A Retrospective StudyJapanese Journal of Clinical Oncology, 2008
- A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerBritish Journal of Cancer, 2008
- Candidate mechanisms for capecitabine‐related hand–foot syndromeBritish Journal of Clinical Pharmacology, 2008
- Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?Clinical Cancer Research, 2008
- Therapy Insight: venous-catheter-related thrombosis in cancer patientsNature Clinical Practice Oncology, 2006
- Mechanism–Based Improvement in the Therapeutic Selectivity of 5-FU Prodrug Alone and Under Conditions of Metabolic ModulationOncology, 1997
- Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and ?-fluoro?-alanineActa Neuropathologica, 1990
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Facilitated transport of uracil and 5‐fluorouracil, and permeation of orotic acid into cultured mammalian cellsJournal of Cellular Physiology, 1980
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957